CoChat

Candidemia in nonneutropenic critically ill patients: Risk factors for non-albicans Candida spp.

Playford, E Geoffrey, Marriott, Deborah, Nguyen, Quoc, Chen, Sharon, Ellis, David, Slavin, Monica, Sorrell, Tania C. · 2008 · Critical Care Medicine
Cited by 156

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Objective: The objective of this study was to determine the clinical features associated with candidemia caused by non-albicans Candida spp. and with potentially fluconazole-resistant Candida spp. (C. glabrata and C. krusei) among candidemic intensive care unit patients. Design: The authors conducted a nationwide prospective cohort study. Setting: The study was conducted in Australian intensive care units. Patients: All patients with intensive care unit-acquired candidemia over a 3-yr period were included in the study. Measurements: Clinical risk factors occurring up to 30 days before candidemia, Candida spp. associated with candidemia, and outcomes were determined. Risk factors associated with either non-albicans Candida spp. or with potentially fluconazole-resistant Candida spp. (C. glabrata or C. krusei) were assessed using multivariate logistic regression. Main Results: Among 179 episodes of intensive care unit-acquired candidemia, C. albicans accounted for 62%, C. glabrata 18%, C. krusei 4%, and other Candida spp. 16%. Independently significant variables associated with non-albicans Candida bloodstream infection included recent prior gastrointestinal surgery (adjusted odds ratio, 2.87; 95% confidence interval, 1.68–4.91) and recent prior systemic antifungal exposure (4.6; 1.36–15.53). Those associated with potentially fluconazole-resistant candidemia included recent prior gastrointestinal surgery (3.31; 1.79–6.11) and recent prior fluconazole exposure (5.47; 1.23–24.32). No significant differences in outcomes were demonstrated for non-albicans or potentially fluconazole-resistant candidemia. Conclusions: Among candidemic intensive care unit patients, prior gastrointestinal surgery and systemic antifungal exposure were significantly associated with both a non-albicans Candida spp. and a potentially fluconazole-resistant Candida spp. LEARNING OBJECTIVES On completion of this article, the reader should be able to: List clinical features discriminating between candidemia caused by C. albicans and those caused by other species. Describe predisposing factors that help discriminate between candidemia which are potentially fluconazole-resistant. Use this information in a clinical setting. Dr. Playford has disclosed that he was a consultant/advisor for Pfizer and Merck; was on the advisory board for Schering-Plough; and is a recipient of grant/research funds from Pfizer and Merck. Dr. Marriott has disclosed that she was/is a recipient of grant/research funds from Pfizer; was/is a consultant/advisor for Merck, Sharpe & Dohme and Sanofi-Pasteur; and was/is on the advisory board for Roche. Dr. Nguyen has disclosed that he has no financial relationships with or interests in any commercial companies pertaining to this educational activity. Dr. Chen has disclosed that she was a recipient of grant/research funds from Pfizer; is a recipient of grant/research funds from Gilead Sciences, Inc.; and is on the advisory board for Gilead Sciences, Inc. and Pfizer Australia. Dr. Ellis has disclosed that he was/is a recipient of grant/research funds from Pfizer Australia, Merck, Sharpe & Dohme Australia, Gilead Sciences Australia, and Schering-Plough Australia; was/is a consultant/advisor for Pfizer Australia, Merck, Sharpe & Dohme Australia, Gilead Sciences Australia, and Schering-Plough Australia; and was/is on the speaker's bureau for Pfizer Australia, Merck, Sharpe & Dohme Australia, Gilead Sciences Australia, and Schering-Plough Australia. Dr. Slavin has disclosed that she was/is a recipient of grant/research funds from Pfizer Inc., Gilead Sciences, Schering-Plough, and Merck and Co.; and was/is on the advisory board for Pfizer Inc., Gilead Sciences, Schering-Plough, and Merck and Co. Dr. Sorrell has disclosed that she was/is a recipient of grant/research funds from Merck, Sharpe & Dohme Australia, Pfizer, and Gilead; and was/is a consultant/advisor for Pfizer, Merck, Gilead, and Schering-Plough. All faculty and staff in a position to control the content of this CME activity have disclosed that they have no financial relationship with, or financial interests in, any commercial companies pertaining to this educational activity. Lippincott CME Institute, Inc., has identified and resolved all faculty conflicts of interest regarding this educational activity. Visit the Critical Care Medicine Web Site (www.ccmjournal.org) for information on obtaining continuing medical education credit.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/ccm.0b013e3181760f42

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 156

Metadata

Authors
Playford, E. G., Marriott, D., Nguyen, Q., Chen, S., Ellis, D., Slavin, M., & Sorrell, T. C.
Venue
Critical Care Medicine
Published
2008-07
Volume
36
Issue
7
Pages
2034-2039
ISSN
0090-3493 (ISSN-L)
OpenAlex
W2062024095
Cited by
156
References
13
FWCI
9.03
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Candidemia in nonneutropenic critically ill patients: Risk factors for non-albicans Candida spp. https://app.cochat.ai/papers/10.1097/ccm.0b013e3181760f42
The paper
Playford, E. G., Marriott, D., Nguyen, Q., Chen, S., Ellis, D., Slavin, M., & Sorrell, T. C. (2008). Candidemia in nonneutropenic critically ill patients: Risk factors for non-albicans Candida spp. Critical Care Medicine. https://doi.org/10.1097/ccm.0b013e3181760f42

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.